Peptic ulcer causes

Jump to navigation Jump to search

Peptic ulcer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Peptic Ulcer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Upper GI Endoscopy

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Endoscopic management
Surgical management

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

2017 ACG Guidelines for Peptic Ulcer Disease

Guidelines for the Indications to Test for, and to Treat, H. pylori Infection

Guidelines for First line Treatment Strategies of Peptic Ulcer Disease for Providers in North America

Guidlines for factors that predict the successful eradication when treating H. pylori infection

Guidelines to document H. pylori antimicrobial resistance in the North America

Guidelines for evaluation and testing of H. pylori antibiotic resistance

Guidelines for when to test for treatment success after H. pylori eradication therapy

Guidelines for penicillin allergy in patients with H. pylori infection

Guidelines for the salvage therapy

Peptic ulcer causes On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Peptic ulcer causes

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Peptic ulcer causes

CDC on Peptic ulcer causes

Peptic ulcer causes in the news

Blogs on Peptic ulcer causes

to Hospitals Treating Peptic ulcer

Risk calculators and risk factors for Peptic ulcer causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Manpreet Kaur, MD [3]

Overview

Peptic ulcer disease (PUD) results from an imbalance between mucosal defense and aggressive factors such as gastric acid, pepsin, and exogenous injury.[1]

The principal causes are:

H. pylori and NSAIDs independently increase ulcer risk and act synergistically. PUD is rare when neither is present.[3]

Less common causes include:

Causes

Summary of causes

Category Cause Contribution / strength of association Clinical clues
Infectious Helicobacter pylori About 42% of PUD.[2] Historically found in 90–95% of duodenal ulcers and 70–90% of gastric ulcers.[7] More strongly linked to duodenal ulcer. cagA-positive strains carry higher risk.[8]
Drug-induced NSAIDs, including low-dose aspirin About 36% of PUD.[2] Independent of, and synergistic with, H. pylori.[3] Many NSAID ulcers are asymptomatic until bleeding or perforation.[9]
Idiopathic H. pylori-negative, NSAID-negative ulcer About 22% of PUD, and rising.[2][10] Diagnosis of exclusion. High risk of rebleeding and death.[11]
Critical illness Stress-related mucosal disease Mucosal lesions are found in 75–100% of ICU patients. Clinically important bleeding occurs in 1–6%.[4] Mechanical ventilation for more than 48 hours, coagulopathy.
Acid hypersecretory Zollinger-Ellison syndrome (gastrinoma) Rare.[5] Multiple, refractory, or atypically located ulcers.
Malignant Gastric cancer, gastric lymphoma Uncommon. Must be excluded.[5] Refractory or non-healing gastric ulcer.
Other infectious Cytomegalovirus, herpes simplex virus, Helicobacter heilmannii Rare.[6] Viral causes mainly in immunocompromised hosts.
Inflammatory / infiltrative Crohn's disease, eosinophilic gastroduodenitis, systemic mastocytosis Rare.[6] Systemic or extraintestinal features of the underlying disease.
Iatrogenic / anatomic Radiation injury, anastomotic (marginal) ulcer, Cameron ulcer Rare.[6] Prior radiation or gastric surgery. Cameron ulcer occurs with a large hiatal hernia.

Helicobacter pylori infection

Helicobacter pylori is the most common identifiable cause of PUD.[2]

Global burden. About 57% (95% CI 44–68%) of PUD worldwide is attributable to H. pylori. This corresponds to about 3.5 million cases that could potentially be prevented by eradication.[12]

Infection is necessary but not sufficient. An infected person has an estimated 10–20% lifetime risk of PUD, at least 3–4 times higher than an uninfected person.[8] In a Danish population-based cohort, H. pylori infection was a major independent risk factor for PUD (OR 4.3, 95% CI 2.2–8.3).[13]

Strain virulence. Infection with cagA-positive strains raises ulcer risk above that of cagA-negative strains. In a nested case-control study, people seropositive for both H. pylori and CagA had odds ratios of:

  • 5.8 (95% CI 1.1–30.0) for duodenal ulcer.
  • 4.4 (95% CI 1.8–10.5) for gastric ulcer.[14]

The gastritis pattern determines ulcer location.

  • Antral-predominant gastritis suppresses somatostatin and increases gastrin release. This causes acid hypersecretion and predisposes to duodenal ulcer.[15]
  • Corpus-predominant gastritis or pangastritis leads to gastric atrophy and low acid output. It predisposes to gastric ulcer and gastric cancer.[15]
  • In a prospective cohort of 1,526 Japanese patients, gastric cancer developed in patients with gastric ulcer but in none of those with duodenal ulcer.[16]

NSAID and aspirin use

NSAIDs, including low-dose aspirin, are an etiologic factor in about 36% of PUD.[2]

Mechanisms of injury. NSAIDs injure the mucosa in two ways:[9][17]

Interaction with H. pylori. A meta-analysis of 16 studies of 1,625 NSAID users found:[3]

  • Uncomplicated PUD was more common in H. pylori-positive than H. pylori-negative users (41.7% vs 25.9%; OR 2.12, 95% CI 1.68–2.67).
  • Compared with H. pylori-negative non-users, H. pylori-infected NSAID users had an ulcer OR of 61.1.
  • H. pylori infection increased the risk of ulcer bleeding 1.79-fold, and NSAID use increased it 4.85-fold.

Clinical presentation. Most NSAID-induced ulcers are asymptomatic, so the first presentation may be a complication.[9]

Idiopathic ulcers

Idiopathic ulcers are H. pylori-negative and NSAID-negative.

Frequency. They account for about 22% of PUD.[2] Their share has risen as H. pylori prevalence has fallen:

  • In Hong Kong, idiopathic ulcers rose from 4.2% to 18.8% of bleeding ulcers between 1997–1998 and 2000.[10]
  • In Asia, the proportion reached 10–30% in studies from the 2000s.[7]

Distinguishing true from pseudo-idiopathic ulcers. Apparent idiopathic ulcers must be separated from:

  • False-negative H. pylori testing. Using two or more diagnostic methods increases sensitivity. Serology is useful in patients taking proton pump inhibitors.[5]
  • Surreptitious NSAID or aspirin use. Platelet cyclooxygenase activity testing can confirm it.[5]

Proposed mechanisms. The pathogenesis of true idiopathic ulcers is not established.[7]

Prognosis. H. pylori-negative idiopathic bleeding ulcers carry a high incidence of recurrent bleeding and mortality.[11]

Other specific causes

  • Stress-related mucosal disease.[4]
    • Upper gastrointestinal mucosal lesions are present in 75–100% of ICU patients, but only 1–6% develop clinically important bleeding.
    • Bleeding risk is predicted by mechanical ventilation for more than 48 hours and by coagulopathy.
    • Stress-ulcer bleeding carries an estimated mortality of 40–50%, mostly from the underlying illness.
  • Acid hypersecretory states. Zollinger-Ellison syndrome is a rare but important cause of refractory gastroduodenal ulcers.[5]
  • Malignancy. Malignancy is a recognized cause of refractory ulcers. Gastric cancer and gastric lymphoma must be excluded in non-healing gastric ulcers.[5]
  • Rare causes. These include:[6]

Contributing factors

These factors increase ulcer risk but are not sole causes. Details belong in the risk factors microchapter.

  • Cigarette smoking
    • Independent risk factor for PUD (OR 3.8, 95% CI 1.7–9.8).[13]
    • Delays ulcer healing.[5]
  • Psychosocial and environmental factors. Risk is increased by psychological stress, family history of PUD, and adverse childhood circumstances such as crowded living conditions and poor water quality.[2]
  • Disaster-related stress. Evidence comes from the 2011 Great East Japan Earthquake:
    • PUD incidence rose 1.5-fold and hemorrhagic ulcers 2.2-fold.
    • Non-H. pylori, non-NSAID ulcers rose from 13% to 24% of cases.[18]
    • Living in a refugee shelter independently predicted ulcer bleeding (OR 4.4, 95% CI 2.1–9.6).[19]

Clinical pearls for etiologic evaluation

  • Establish H. pylori status in every patient with PUD. Take a detailed, repeated NSAID and aspirin history that includes over-the-counter products.[5][20]
  • Do not accept a single negative H. pylori test while the patient is on a PPI. Use two or more methods, or serology.[5]
  • Before labeling an ulcer idiopathic, exclude:[5][6]
    • False-negative H. pylori testing.
    • Occult NSAID or aspirin use.
    • Malignancy.
    • Zollinger-Ellison syndrome.
  • A silent ulcer, especially one presenting with bleeding or perforation, should raise suspicion for NSAID use.[9]

References

  1. ↑ Lanas A, Chan FKL (2017). "Peptic ulcer disease". Lancet. 390 (10094): 613–624.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Vakil N (2024). "Peptic ulcer disease: a review". JAMA. 332 (21): 1832–1842. doi:10.1001/jama.2024.19094.
  3. ↑ 3.0 3.1 3.2 Huang JQ, Sridhar S, Hunt RH (2002). "Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis". Lancet. 359 (9300): 14–22.
  4. ↑ 4.0 4.1 4.2 Bardou M, Quenot JP, Barkun A (2015). "Stress-related mucosal disease in the critically ill patient". Nat Rev Gastroenterol Hepatol. 12 (2): 98–107. doi:10.1038/nrgastro.2014.235. PMID 25560847.
  5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 Kim HU (2015). "Diagnostic and treatment approaches for refractory peptic ulcers". Clin Endosc. 48 (4): 285–290. PMID 26240800.
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 McColl KE (2009). "How I manage H. pylori-negative, NSAID/aspirin-negative peptic ulcers". Am J Gastroenterol. 104 (1): 190–193.
  7. ↑ 7.0 7.1 7.2 Iijima K, Kanno T, Koike T, Shimosegawa T (2014). "Helicobacter pylori-negative, non-steroidal anti-inflammatory drug: negative idiopathic ulcers in Asia". World J Gastroenterol. 20 (3): 706–713. doi:10.3748/wjg.v20.i3.706.
  8. ↑ 8.0 8.1 Kuipers EJ, Thijs JC, Festen HP (1995). "The prevalence of Helicobacter pylori in peptic ulcer disease". Aliment Pharmacol Ther. 9 (Suppl 2): 59–69. PMID 8547530.
  9. ↑ 9.0 9.1 9.2 9.3 Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract (review). Dig Dis. 1995;13(2):119. https://karger.com/ddi/article/13/2/119/93773
  10. ↑ 10.0 10.1 Hung LC, Ching JY, Sung JJ; et al. (2005). "Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study". Gastroenterology. 128 (7): 1845–1850. PMID 15940620.
  11. ↑ 11.0 11.1 Wong GL, Wong VW, Chan Y; et al. (2009). "High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers". Gastroenterology. 137 (2): 525–531. doi:10.1053/j.gastro.2009.05.006. PMID 19445937.
  12. ↑ Mülder DT, O'Mahony JF, Kapteijn N; et al. (2026). "The disease burden of Helicobacter pylori beyond gastric cancer: quantifying the forgotten potential benefits of mass eradication". Gastroenterology. 170: 344–352. doi:10.1053/j.gastro.2025.08.015.
  13. ↑ 13.0 13.1 Rosenstock S, Jørgensen T, Bonnevie O, Andersen L (2003). "Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults". Gut. 52 (2): 186–193. doi:10.1136/gut.52.2.186.
  14. ↑ Nomura AM, Pérez-Pérez GI, Lee J, Stemmermann G, Blaser MJ. Relation between Helicobacter pylori cagA status and risk of peptic ulcer disease. Am J Epidemiol. 2002.
  15. ↑ 15.0 15.1 Calam J, Baron JH. ABC of the upper gastrointestinal tract: pathophysiology of duodenal and gastric ulcer and gastric cancer. BMJ. 2001;323:980–982.
  16. ↑ Uemura N, Okamoto S, Yamamoto S; et al. (2001). "Helicobacter pylori infection and the development of gastric cancer". N Engl J Med. 345 (11): 784–789. PMID 11556297.
  17. ↑ Drini M (2017). "Peptic ulcer disease and non-steroidal anti-inflammatory drugs". Aust Prescr. 40 (3): 91–93.
  18. ↑ Kanno T, Iijima K, Abe Y, et al. Peptic ulcers after the Great East Japan earthquake and tsunami: possible existence of psychosocial stress ulcers in humans. J Gastroenterol. 2013.
  19. ↑ Kanno T, Iijima K, Abe Y; et al. (2015). "Accommodation in a refugee shelter as a risk factor for peptic ulcer bleeding after the Great East Japan Earthquake: a case–control study of 329 patients". J Gastroenterol. doi:10.1007/s00535-014-0940-4.
  20. ↑ Kamada T; et al. (2021). "Evidence-based clinical practice guidelines for peptic ulcer disease 2020". J Gastroenterol. 56 (4): 303–322. doi:10.1007/s00535-021-01769-0. PMID 33620586 Check |pmid= value (help).